Analyst Price Targets — VIR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 11:20 am | — | Morgan Stanley | $25.00 | $9.11 | TheFly | Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley |
| June 11, 2026 11:24 am | — | Morgan Stanley | $27.00 | $8.25 | TheFly | Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley |
| May 8, 2026 1:28 pm | — | Morgan Stanley | $23.00 | $9.38 | TheFly | Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley |
| March 4, 2026 11:41 am | Patrick Trucchio | H.C. Wainwright | $20.00 | $9.13 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright |
| February 26, 2026 6:07 pm | Roanna Ruiz | Leerink Partners | $20.00 | $9.33 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners |
| February 24, 2026 7:22 pm | — | Barclays | $30.00 | $9.49 | TheFly | Vir Biotechnology price target raised to $30 from $26 at Barclays |
| February 24, 2026 1:02 pm | Cory Kasimov | Evercore ISI | $18.00 | $9.70 | TheFly | Vir Biotechnology price target raised to $18 from $12 at Evercore ISI |
| February 24, 2026 12:05 pm | Joseph Stringer | Needham | $18.00 | $9.64 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $18 at Needham |
| February 24, 2026 11:49 am | Michael Ulz | Morgan Stanley | $24.00 | $7.43 | TheFly | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley |
| February 24, 2026 11:05 am | Sean McCutcheon | Raymond James | $19.00 | $9.69 | StreetInsider | Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy |
Latest News for VIR
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York. A live webcast of the fireside chat will be available at https://investors.vir.bio…
Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804,977 shares of the company's stock after buying an additional 315,969 shares during the period. Algert Global LLC owned
ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,456,677 shares of the company's stock, valued at approximately $25,034,000. Vir Biotechnology comprises 1.1% of ADAR1
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500. The company ended the quarter with approximately $1.01 billion in cash, cash equivalents and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VIR.
U.S. House Trading
No House trades found for VIR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.